The impact of histological subtype on postoperative recurrence pattern and timing in locally advanced esophagogastric junction cancer

被引:0
作者
Maeda, Shinsuke [1 ]
Ota, Masaho [2 ]
Ito, Shunichi [1 ]
Hosoda, Kei [1 ]
机构
[1] Tokyo Womens Med Univ, Inst Gastroenterol, Dept Surg, 8-1 Kawadacho,Shinjuku Ku, Tokyo 1628666, Japan
[2] Tokyo Womens Med Univ, Yachiyo Med Ctr, Div Gastroenterol Surg, Chiba, Japan
关键词
Esophagogastric junction; Histological subtype; Recurrence pattern; Recurrence timing; ESOPHAGEAL CANCER; PREOPERATIVE CHEMORADIOTHERAPY; GASTROESOPHAGEAL JUNCTION; ADENOCARCINOMA; SURGERY; CLASSIFICATION;
D O I
10.1007/s12672-024-01353-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThe differences in tumor behavior between adenocarcinoma (AC) and squamous cell carcinoma (SCC) of the esophagogastric junction (EGJ) have yet to be well investigated. The purpose of this study was to gain insights that can contribute to tailored treatments and follow-up strategies by analyzing the correlation between histological subtypes and oncological outcomes.MethodsA retrospective analysis was used to determine the characteristics of the histological subtypes of EGJ cancer by comparing the appearance of postoperative recurrence. A total of 102 consecutive patients with pathological stage IIA to IVA EGJ cancer, who underwent R0 surgery in our department from 2004 to 2020, were enrolled. The recurrence pattern, timing, survival, and potential prognostic factors were compared.ResultsAfter a median follow-up time of 70.1 months, the AC group demonstrated comparable lymph node failure-free survival (P = 0.291) and significantly worse non-lymphogenous recurrence-free survival (P = 0.035) than did the SCC group. A significantly longer period from surgery to recurrence was also observed in the AC group (P = 0.029). Multivariate analysis indicated that histological subtype (P = 0.015, 95% CI 1.24-7.28) was significantly correlated with the incidence of non-lymphogenous recurrence.ConclusionsThe pattern and timing of postoperative recurrence were significantly different between the histological subtypes of EGJ cancer. Compared with EGJ SCC, EGJ AC may have a greater tendency toward non-lymphogenous progression and a greater propensity for longer surgery-to-recurrence periods.
引用
收藏
页数:12
相关论文
共 28 条
  • [1] Recurrence after Esophagectomy for Adenocarcinoma: Defining Optimal Follow-Up Intervals and Testing
    Abate, Emmanuele
    DeMeester, Steven R.
    Zehetner, Joerg
    Oezcelik, Arzu
    Ayazi, Shahin
    Costales, Jesse
    Banki, Farzaneh
    Lipham, John C.
    Hagen, Jeffrey A.
    DeMeester, Tom R.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2010, 210 (04) : 428 - 435
  • [2] Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
    Al-Batran, Salah-Eddin
    Homann, Nils
    Pauligk, Claudia
    Goetze, Thorsten O.
    Meiler, Johannes
    Kasper, Stefan
    Kopp, Hans-Georg
    Mayer, Frank
    Haag, Georg Martin
    Luley, Kim
    Lindig, Udo
    Schmiegel, Wolff
    Pohl, Michael
    Stoehlmacher, Jan
    Folprecht, Gunnar
    Probst, Stephan
    Prasnikar, Nicole
    Fischbach, Wolfgang
    Mahlberg, Rolf
    Trojan, Joerg
    Koenigsmann, Michael
    Martens, Uwe M.
    Thuss-Patience, Peter
    Egger, Matthias
    Block, Andreas
    Heinemann, Volker
    Illerhaus, Gerald
    Moehler, Markus
    Schenk, Michael
    Kullmann, Frank
    Behringer, Dirk M.
    Heike, Michael
    Pink, Daniel
    Teschendorf, Christian
    Loehr, Carmen
    Bernhard, Helga
    Schuch, Gunter
    Rethwisch, Volker
    von Weikersthal, Ludwig Fischer
    Hartmann, Joerg T.
    Kneba, Michael
    Daum, Severin
    Schulmann, Karsten
    Weniger, Joerg
    Belle, Sebastian
    Gaiser, Timo
    Oduncu, Fuat S.
    Guentner, Martina
    Hozaeel, Wael
    Reichart, Alexander
    [J]. LANCET, 2019, 393 (10184) : 1948 - 1957
  • [3] Global incidence of oesophageal cancer by histological subtype in 2012
    Arnold, Melina
    Soerjomataram, Isabelle
    Ferlay, Jacques
    Forman, David
    [J]. GUT, 2015, 64 (03) : 381 - 387
  • [4] The Epidemiology of Esophageal Adenocarcinoma
    Coleman, Helen G.
    Xie, Shao-Hua
    Lagergren, Jesper
    [J]. GASTROENTEROLOGY, 2018, 154 (02) : 390 - 405
  • [5] Pattern of recurrence after surgery in adenocarcinoma of the gastro-oesophageal junction
    de Manzoni, G
    Pedrazzani, C
    Pasini, F
    Durante, E
    Gabbani, M
    Grandinetti, A
    Guglielmi, A
    Griso, C
    Cordiano, C
    [J]. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2003, 29 (06): : 506 - 510
  • [6] Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey
    Dindo, D
    Demartines, N
    Clavien, PA
    [J]. ANNALS OF SURGERY, 2004, 240 (02) : 205 - 213
  • [7] Hosokawa Y, 2014, ANTICANCER RES, V34, P4391
  • [8] Japanese Classification of Esophageal Cancer, 11th Edition: part II and III
    Japan Esophageal Society
    [J]. ESOPHAGUS, 2017, 14 (01) : 37 - 65
  • [9] Japanese Classification of Esophageal Cancer, 11th Edition: part I
    Japan Esophageal Society
    [J]. ESOPHAGUS, 2017, 14 (01) : 1 - 36
  • [10] A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant
    Kato, Ken
    Ito, Yoshinori
    Daiko, Hiroyuki
    Ozawa, Soji
    Ogata, Takashi
    Hara, Hiroki
    Kojima, Takashi
    Abe, Tetsuya
    Bamba, Takeo
    Watanabe, Masaya
    Kawakubo, Hirofumi
    Shibuya, Yuichi
    Tsubosa, Yasuhiro
    Takegawa, Naoki
    Kajiwara, Takeshi
    Baba, Hideo
    Ueno, Masaki
    Machida, Ryunosuke
    Nakamura, Kenichi
    Kitagawa, Yuko
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)